{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:53:04Z","timestamp":1794441184885,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The renin\u2013angiotensin system (RAS) plays a crucial role in regulating blood pressure and the cardio-renal system. The classical RAS, mainly mediated by angiotensin I, angiotensin-converting enzyme, and angiotensin II, has been reported to be altered in critically ill patients, such as those in vasodilatory shock. However, recent research has highlighted the role of some components of the counterregulatory axis of the classical RAS, termed the alternative RAS, such as angiotensin-converting Enzyme 2 (ACE2) and angiotensin-(1\u20137), or peptidases which can modulate the RAS like dipeptidyl-peptidase 3, in many critical situations. In cases of shock, dipeptidyl-peptidase 3, an enzyme involved in the degradation of angiotensin and opioid peptides, has been associated with acute kidney injury and mortality and preclinical studies have tested its neutralization. Angiotensin-(1\u20137) has been shown to prevent septic shock development and improve outcomes in experimental models of sepsis. In the context of experimental acute lung injury, ACE2 activity has demonstrated a protective role, and its inactivation has been associated with worsened lung function, leading to the use of active recombinant human ACE2, in preclinical and human studies. Angiotensin-(1\u20137) has been tested in experimental models of acute lung injury and in a recent randomized controlled trial for patients with COVID-19 related hypoxemia. Overall, the alternative RAS appears to have a role in the pathogenesis of disease in critically ill patients, and modulation of the alternative RAS may improve outcomes. Here, we review the available evidence regarding the methods of analysis of the RAS, pathophysiological disturbances of this system, and discuss how therapeutic manipulation may improve outcomes in the critically ill.<\/jats:p>","DOI":"10.1186\/s13054-023-04739-5","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:02:59Z","timestamp":1700488979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The alternative renin\u2013angiotensin system in critically ill patients: pathophysiology and therapeutic implications"],"prefix":"10.1186","volume":"27","author":[{"given":"Bruno","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zarbock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"4739_CR1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2009070759","volume":"21","author":"J Peti-Peterdi","year":"2010","unstructured":"Peti-Peterdi J, Harris RC. Macula Densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010;21:1093\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"4739_CR2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1161\/01.CIR.102.16.2011","volume":"102","author":"SE Orfanos","year":"2000","unstructured":"Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation. 2000;102:2011\u20138.","journal-title":"Circulation"},{"key":"4739_CR3","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol-cell Physiol. 2007;292:C82-97.","journal-title":"Am J Physiol-cell Physiol"},{"key":"4739_CR4","doi-asserted-by":"crossref","unstructured":"Li* Q, Feenstra\u2020 M, Pfaffendorf* M, Eijsman\u2020 L, Zwieten*\u2020 PA van. Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J Cardiovasc Pharmacol. 1997;29:451\u20136.","DOI":"10.1097\/00005344-199704000-00004"},{"key":"4739_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1046\/j.1523-1755.2002.00365.x","volume":"61","author":"G Wolf","year":"2002","unstructured":"Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RAK, Thaiss F. Angiotensin II activates nuclear transcription factor-\u03baB through AT1 and AT2 receptors 1. Kidney Int. 2002;61:1986\u201395.","journal-title":"Kidney Int"},{"key":"4739_CR6","first-page":"567","volume":"267","author":"F Qadri","year":"1993","unstructured":"Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger T. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus. J Pharmacol Exp Ther. 1993;267:567\u201374.","journal-title":"J Pharmacol Exp Ther"},{"key":"4739_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1161\/01.CIR.89.5.2273","volume":"89","author":"B Schieffer","year":"2018","unstructured":"Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 2018;89:2273\u201382.","journal-title":"Circulation"},{"key":"4739_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0303-7207(92)90101-B","volume":"90","author":"G Aguilera","year":"1992","unstructured":"Aguilera G. Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol. 1992;90:53\u201360.","journal-title":"Mol Cell Endocrinol"},{"key":"4739_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","volume":"24","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Critical Care Lond Engl. 2020;24:43.","journal-title":"Critical Care Lond Engl"},{"key":"4739_CR10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and survival in patients given angiotensin ii for catecholamine-resistant vasodilatory shock. a clinical trial. Am J Resp Crit Care. 2020;202:1253\u201361.","journal-title":"Am J Resp Crit Care."},{"key":"4739_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","volume":"47","author":"PJ Gleeson","year":"2019","unstructured":"Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Meerhaeghe TV, Brimioulle S, et al. Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit Care Med. 2019;47:152\u20138.","journal-title":"Crit Care Med"},{"key":"4739_CR12","doi-asserted-by":"crossref","unstructured":"Leisman DE, Fernandes TD, Bijol V, Abraham MN, Lehman JR, Taylor MD, et al. Impaired angiotensin II type 1 receptor signaling contributes to sepsis induced acute kidney injury. Kidney Int. 2020.07.047.","DOI":"10.1016\/j.kint.2020.07.047"},{"key":"4739_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1161\/01.HYP.38.2.177","volume":"38","author":"M Bucher","year":"2001","unstructured":"Bucher M, Ittner K-P, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension. 2001;38:177\u201382.","journal-title":"Hypertension"},{"key":"4739_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2\/Angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev. 2018;98:505\u201353.","journal-title":"Physiol Rev"},{"key":"4739_CR15","doi-asserted-by":"publisher","first-page":"13711","DOI":"10.1074\/jbc.RA120.014183","volume":"295","author":"S Jha","year":"2020","unstructured":"Jha S, Taschler U, Domenig O, Poglitsch M, Bourgeois B, Pollheimer M, et al. Dipeptidyl peptidase 3 modulates the renin\u2013angiotensin system in mice. J Biol Chem. 2020;295:13711\u201323.","journal-title":"J Biol Chem"},{"key":"4739_CR16","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","volume":"63","author":"RA Santos","year":"2014","unstructured":"Santos RA. Angiotensin-(1\u20137). Hypertension. 2014;63:1138\u201347.","journal-title":"Hypertension"},{"key":"4739_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1161\/01.CIR.0000094734.67990.99","volume":"108","author":"LS Zisman","year":"2003","unstructured":"Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin-(1\u20137)\u2013forming activity in failing human heart ventricles. Circulation. 2003;108:1707\u201312.","journal-title":"Circulation"},{"key":"4739_CR18","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res. 2000;87:E1-9.","journal-title":"Circ Res"},{"key":"4739_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/01.HYP.19.6.692","volume":"19","author":"K Yamamoto","year":"2018","unstructured":"Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 34.24.11) in spontaneously hypertensive rats. Hypertension. 2018;19:692\u20136.","journal-title":"Hypertension"},{"key":"4739_CR20","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1161\/01.CIR.0000160867.23556.7D","volume":"111","author":"E Kostenis","year":"2005","unstructured":"Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-Protein\u2013coupled receptor mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005;111:1806\u201313.","journal-title":"Circulation"},{"key":"4739_CR21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1681\/ASN.V991716","volume":"9","author":"CM Ferrario","year":"1998","unstructured":"Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol. 1998;9:1716\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"4739_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FJC.0b013e3182588b32","volume":"60","author":"MA Garcia-Espinosa","year":"2012","unstructured":"Garcia-Espinosa MA, Shaltout HA, Gallagher PE, Chappell MC, Diz DI. In vivo expression of angiotensin-(1\u20137) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 Rats. J Cardiovasc Pharmacol. 2012;60:150\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"4739_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/01.HYP.29.1.394","volume":"29","author":"P Li","year":"1997","unstructured":"Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1\u20137) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394\u20138.","journal-title":"Hypertension"},{"key":"4739_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/01.HYP.38.3.665","volume":"38","author":"AJ Ferreira","year":"2001","unstructured":"Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1\u20137): cardioprotective effect in myocardial ischemia\/reperfusion. Hypertension. 2001;38:665\u20138.","journal-title":"Hypertension"},{"key":"4739_CR25","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.4049\/jimmunol.1000314","volume":"185","author":"KD da Silveira","year":"2010","unstructured":"da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. Anti-Inflammatory effects of the activation of the angiotensin-(1\u20137) receptor, mas, in experimental models of arthritis. J Immunol. 2010;185:5569\u201376.","journal-title":"J Immunol"},{"key":"4739_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.117.09679","volume":"70","author":"SN Patel","year":"2017","unstructured":"Patel SN, Ali Q, Samuel P, Steckelings UM, Hussain T. Angiotensin II type 2 receptor and receptor mas are colocalized and functionally interdependent in obese Zucker rat kidney. Hypertension. 2017;70:831\u20138.","journal-title":"Hypertension"},{"key":"4739_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20130515","volume":"128","author":"D Villela","year":"2014","unstructured":"Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci. 2014;128:227\u201334.","journal-title":"Clin Sci"},{"key":"4739_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/HYPERTENSIONAHA.116.08814","volume":"69","author":"J Leonhardt","year":"2018","unstructured":"Leonhardt J, Villela DC, Teichmann A, M\u00fcnter L-M, Mayer MC, Mardahl M, et al. Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS. Hypertension. 2018;69:1128\u201335.","journal-title":"Hypertension"},{"key":"4739_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","volume":"32","author":"MP Ocaranza","year":"2014","unstructured":"Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, et al. Angiotensin-(1\u20139) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme & Ang II axis. J Hypertens. 2014;32:771\u201383.","journal-title":"J Hypertens"},{"key":"4739_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.phrs.2018.07.022","volume":"135","author":"E Mendoza-Torres","year":"2018","unstructured":"Mendoza-Torres E, Riquelme JA, Vielma A, Sagredo AR, Gabrielli L, Bravo-Sagua R, et al. Protection of the myocardium against ischemia\/reperfusion injury by angiotensin-(1\u20139) through an AT2R and Akt-dependent mechanism. Pharmacol Res. 2018;135:112\u201321.","journal-title":"Pharmacol Res"},{"key":"4739_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/HJH.0b013e328335d291","volume":"28","author":"MP Ocaranza","year":"2010","unstructured":"Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, et al. Angiotensin-(1\u20139) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28:1054\u201364.","journal-title":"J Hypertens"},{"key":"4739_CR32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.107.103242","volume":"51","author":"SH Padia","year":"2008","unstructured":"Padia SH, Kemp BA, Howell NL, Fournie-Zaluski M-C, Roques BP, Carey RM. Conversion of renal angiotensin ii to angiotensin iii is critical for AT2 receptor-mediated natriuresis in rats. Hypertension. 2008;51:460\u20135.","journal-title":"Hypertension"},{"key":"4739_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","volume":"31","author":"MC Chappell","year":"1998","unstructured":"Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1\u20137) by angiotensin-converting enzyme. Hypertension. 1998;31:362\u20137.","journal-title":"Hypertension"},{"key":"4739_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","volume":"112","author":"RQ Lautner","year":"2013","unstructured":"Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. Discovery and characterization of alamandine. Circ Res. 2013;112:1104\u201311.","journal-title":"Circ Res"},{"key":"4739_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/01.mnh.0000441052.44406.92","volume":"23","author":"DC Villela","year":"2014","unstructured":"Villela DC, Passos-Silva DG, Santos RAS. Alamandine. Curr Opin Nephrol. 2014;23:130\u20134.","journal-title":"Curr Opin Nephrol"},{"key":"4739_CR36","doi-asserted-by":"publisher","first-page":"H123","DOI":"10.1152\/ajpheart.00075.2018","volume":"316","author":"AC Oliveira","year":"2019","unstructured":"Oliveira AC, Melo MB, Motta-Santos D, Peluso AA, Souza-Neto F, da Silva RF, et al. Genetic deletion of the alamandine receptor MRGD leads to dilated cardiomyopathy in mice. Am J Physiol - Heart Circ. 2019;316:H123\u201333.","journal-title":"Am J Physiol - Heart Circ"},{"key":"4739_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"MP Ocaranza","year":"2020","unstructured":"Ocaranza MP, Riquelme JA, Garc\u00eda L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin\u2013angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17:116\u201329.","journal-title":"Nat Rev Cardiol"},{"key":"4739_CR38","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"SJ Forrester","year":"2018","unstructured":"Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98:1627\u2013738.","journal-title":"Physiol Rev"},{"key":"4739_CR39","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1007\/s00018-004-4246-1","volume":"61","author":"SY Chai","year":"2004","unstructured":"Chai SY, Fernando R, Peck G, Ye S-Y, Mendelsohn FAO, Jenkins TA, et al. What\u2019s new in the renin-angiotensin system? Cell Mol Life Sci CMLS. 2004;61:2728\u201337.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"4739_CR40","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1111\/j.1742-4658.2011.08275.x","volume":"278","author":"SC Prajapati","year":"2011","unstructured":"Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J. 2011;278:3256\u201376.","journal-title":"FEBS J"},{"key":"4739_CR41","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/febs.16429","volume":"290","author":"G Malovan","year":"2023","unstructured":"Malovan G, Hierzberger B, Suraci S, Schaefer M, Santos K, Jha S, et al. The emerging role of dipeptidyl peptidase 3 in pathophysiology. FEBS J. 2023;290:2246\u201362.","journal-title":"FEBS J"},{"key":"4739_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.peptides.2016.06.005","volume":"83","author":"N Cruz-Diaz","year":"2016","unstructured":"Cruz-Diaz N, Wilson BA, Pirro NT, Brosnihan KB, Marshall AC, Chappell MC. Identification of dipeptidyl peptidase 3 as the Angiotensin-(1\u20137) degrading peptidase in human HK-2 renal epithelial cells. Peptides. 2016;83:29\u201337.","journal-title":"Peptides"},{"key":"4739_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1373\/jalm.2018.027995","volume":"3","author":"L Rehfeld","year":"2019","unstructured":"Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med. 2019;3:943\u201353.","journal-title":"J Appl Lab Med"},{"key":"4739_CR44","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol - Heart Circ. 2016;310:H137\u201352.","journal-title":"Am J Physiol - Heart Circ"},{"key":"4739_CR45","doi-asserted-by":"crossref","unstructured":"Reindl-Schwaighofer R, H\u00f6dlmoser S, Eskandary F, Poglitsch M, Bonderman D, Strassl R, et al. Angiotensin-Converting Enzyme 2 (ACE2) Elevation in Severe COVID-19. Am. J. Respir. Crit. Care Med. 2021;01\u20130142le.","DOI":"10.1164\/rccm.202101-0142LE"},{"key":"4739_CR46","first-page":"e29","volume":"77","author":"MC Chappell","year":"2020","unstructured":"Chappell MC, Pirro NT, South AM, Gwathmey TM. Concerns on the specificity of commercial ELISAs for the measurement of angiotensin-(1\u20137) and angiotensin ii in human plasma. Hypertension. 2020;77:e29-31.","journal-title":"Hypertension"},{"key":"4739_CR47","doi-asserted-by":"publisher","first-page":"1012452","DOI":"10.3389\/fcvm.2022.1012452","volume":"9","author":"D van Lier","year":"2022","unstructured":"van Lier D, Kox M, Pickkers P. Commentary: Plasma angiotensin II is increased in critical coronavirus disease 2019. Front Cardiovasc Med. 2022;9:1012452.","journal-title":"Front Cardiovasc Med"},{"key":"4739_CR48","doi-asserted-by":"crossref","unstructured":"Pode-Shakked N, Ceschia G, Rose JE, Goldstein SL, Stanski NL, Investigators the G of PSS. Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock. Crit Care. 2023;27:230.","DOI":"10.1186\/s13054-023-04518-2"},{"key":"4739_CR49","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/CIRCRESAHA.123.321883","volume":"132","author":"MC Chappell","year":"2023","unstructured":"Chappell MC. Renin-angiotensin system and sex differences in COVID-19: a critical assessment. Circ Res. 2023;132:1320\u201337.","journal-title":"Circ Res"},{"key":"4739_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13054-022-04161-3","volume":"26","author":"B Garcia","year":"2022","unstructured":"Garcia B, Su F, Dewachter L, Favory R, Khaldi A, Moiroux-Sahraoui A, et al. Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock. Crit Care. 2022;26:281.","journal-title":"Crit Care"},{"key":"4739_CR51","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949\u201357.","journal-title":"Crit Care Med"},{"key":"4739_CR52","doi-asserted-by":"crossref","unstructured":"Chawla LS, Bellomo R. Reply to: Alteration of the renin-angiotensin-aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. 2020;10\u20133968le.","DOI":"10.1164\/rccm.202010-3968LE"},{"key":"4739_CR53","doi-asserted-by":"crossref","unstructured":"Picod A, Deniau B, Ayar PV, Genest M, Julian N, Azibani F, et al. Alteration of the Renin-Angiotensin-Aldosterone System in Shock: Role of the Dipeptidyl Peptidase 3. Am J Respir Crit Care Med 2020;10\u20133873le.","DOI":"10.1164\/rccm.202010-3873LE"},{"key":"4739_CR54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.34067\/KID.0001562021","volume":"360","author":"KA Nath","year":"2021","unstructured":"Nath KA, Singh RD, Grande JP, Garovic VD, Croatt AJ, Ackerman AW, et al. Expression of ACE2 in the Intact and Acutely Injured Kidney. Kidney. 2021;360:1095\u2013106.","journal-title":"Kidney."},{"key":"4739_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.601909","volume":"12","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu D, Deng F, Yan Y, Li J, Zhang C, et al. Angiotensin (1\u20137) attenuates sepsis-induced acute kidney injury by regulating the NF-\u03baB pathway. Front Pharmacol. 2021;12: 601909.","journal-title":"Front Pharmacol"},{"key":"4739_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.600163","volume":"12","author":"N Fatima","year":"2021","unstructured":"Fatima N, Patel S, Hussain T. Angiotensin AT2 receptor is anti-inflammatory and reno-protective in lipopolysaccharide mice model: role of IL-10. Front Pharmacol. 2021;12: 600163.","journal-title":"Front Pharmacol"},{"key":"4739_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13054-018-2210-y","volume":"22","author":"H-J Tsai","year":"2018","unstructured":"Tsai H-J, Liao M-H, Shih C-C, Ka S-M, Tsao C-M, Wu C-C. Angiotensin-(1\u20137) attenuates organ injury and mortality in rats with polymicrobial sepsis. Crit Care. 2018;22:269.","journal-title":"Crit Care"},{"key":"4739_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13054-023-04396-8","volume":"27","author":"B Garcia","year":"2023","unstructured":"Garcia B, Su F, Manicone F, Dewachter L, Favory R, Khaldi A, et al. Angiotensin 1\u20137 in an experimental septic shock model. Crit Care. 2023;27:106.","journal-title":"Crit Care"},{"key":"4739_CR59","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1097\/00003246-200109000-00016","volume":"29","author":"M Bucher","year":"2001","unstructured":"Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med. 2001;29:1750\u20135.","journal-title":"Crit Care Med"},{"key":"4739_CR60","doi-asserted-by":"crossref","unstructured":"Shih C-C, Chen S-J, Chang W-K, Tsai H-J, Huang H-C, Wu C-C, et al. Stimulation of angiotensin II type 2 receptor attenuates organ injury in rats with polymicrobial sepsis. J Chin Med Assoc. 2023; 688\u2013695.","DOI":"10.1097\/JCMA.0000000000000911"},{"key":"4739_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238039","volume":"15","author":"B Deniau","year":"2020","unstructured":"Deniau B, Blet A, Santos K, Ayar PV, Genest M, K\u00e4storf M, et al. Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study. PLoS ONE. 2020;15: e0238039.","journal-title":"PLoS ONE"},{"key":"4739_CR62","first-page":"344","volume":"22","author":"L Bitker","year":"2020","unstructured":"Bitker L, Patel S, Bittar I, Eastwood G, Bellomo R, Burrell L. Reduced urinary levels of angiotensin-converting enzyme 2 activity predict acute kidney injury in critically ill patients. Crit Care Resusc. 2020;22:344\u201354.","journal-title":"Crit Care Resusc"},{"key":"4739_CR63","first-page":"185","volume":"14","author":"A Picod","year":"2022","unstructured":"Picod A, Genest M, Assad N, Polidano E, Placier S, Gaudry S, et al. Circulating dipeptidyl peptidase 3 modulates hemodynamics and the renin-angiotensin-aldosterone system in mice. Archives Cardiovasc Dis Suppl. 2022;14:185.","journal-title":"Archives Cardiovasc Dis Suppl"},{"key":"4739_CR64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13054-021-03471-2","volume":"25","author":"A Blet","year":"2021","unstructured":"Blet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X, et al. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care. 2021;25:61.","journal-title":"Crit Care"},{"key":"4739_CR65","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.bja.2021.11.021","volume":"128","author":"B Deniau","year":"2022","unstructured":"Deniau B, Picod A, Lier DV, Ayar PV, Santos K, Hartmann O, et al. High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Brit J Anaesth. 2022;128:e54\u20137.","journal-title":"Brit J Anaesth"},{"key":"4739_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154383","volume":"78","author":"D van Lier","year":"2023","unstructured":"van Lier D, Beunders R, Kox M, Pickkers P. Associations of dipeptidyl-peptidase 3 with short-term outcome in a mixed admission ICU-cohort. J Crit Care. 2023;78: 154383.","journal-title":"J Crit Care"},{"key":"4739_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13054-020-02888-5","volume":"24","author":"F D\u00e9pret","year":"2020","unstructured":"D\u00e9pret F, Amzallag J, Pollina A, Fayolle-Pivot L, Coutrot M, Chaussard M, et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. Crit Care. 2020;24:168.","journal-title":"Crit Care"},{"key":"4739_CR68","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1164\/rccm.202005-2050OC","volume":"203","author":"M K\u00fcllmar","year":"2021","unstructured":"K\u00fcllmar M, Saadat-Gilani K, Weiss R, Massoth C, Lagan A, Cort\u00e9s MN, et al. Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients. Am J Respir Crit Care Med. 2021;203:1119\u201326.","journal-title":"Am J Respir Crit Care Med"},{"key":"4739_CR69","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1164\/rccm.202012-4419ED","volume":"203","author":"M Legrand","year":"2021","unstructured":"Legrand M, Bokoch MP. The yin and yang of the renin\u2013angiotensin\u2013aldosterone system in acute kidney injury. Am J Respir Crit Care Med. 2021;203:1053\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"4739_CR70","doi-asserted-by":"crossref","unstructured":"Lier D van, Beunders R, Kox M, Pickkers P. The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavourable outcomes after cardiac surgery: A prospective cohort study. Eur J Anaesth. 2022;342\u201351.","DOI":"10.1097\/EJA.0000000000001662"},{"key":"4739_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature"},{"key":"4739_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40635-015-0044-3","volume":"3","author":"V Zambelli","year":"2015","unstructured":"Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, et al. Angiotensin-(1\u20137) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. Intensive Care Med Exp. 2015;3:8.","journal-title":"Intensive Care Med Exp"},{"key":"4739_CR73","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1164\/rccm.202012-4461OC","volume":"204","author":"L Gerard","year":"2021","unstructured":"Gerard L, Lecocq M, Bouzin C, Hoton D, Schmit G, Pereira JP, et al. Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19\u2013related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2021;204:1024\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"4739_CR74","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201912-2504LE","volume":"202","author":"K Krenn","year":"2020","unstructured":"Krenn K, H\u00f6bart P, Poglitsch M, Croiz\u00e9 A, Ullrich R. Equilibrium angiotensin metabolite profiling in patients with acute respiratory distress syndrome indicates angiotensin converting enzyme inhibition. Am J Respir Crit Care Med. 2020;202:1253\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"4739_CR75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234.","journal-title":"Crit Care"},{"key":"4739_CR76","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","volume":"8","author":"A Zoufaly","year":"2020","unstructured":"Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8:1154\u20138.","journal-title":"Lancet Respir Med"},{"key":"4739_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-022-04096-9","volume":"26","author":"G Wagener","year":"2022","unstructured":"Wagener G, Goldklang MP, Gerber A, Elisman K, Eiseman KA, Fonseca LD, et al. A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1\u20137 (TXA-127) for the treatment of severe COVID-19. Crit Care. 2022;26:229.","journal-title":"Crit Care"},{"key":"4739_CR78","unstructured":"Martins ALV, Annoni F, Silva FA da, Bolais-Ramos L, Oliveira GC de, Matos AH dos S, et al. Angiotensin 1\u20137 in severe COVID-19 patients: a phase 1 clinical trial. Medrxiv. 2022;2022.09.15.22279897."},{"key":"4739_CR79","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2023.3546","volume":"329","author":"WH Self","year":"2023","unstructured":"Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, et al. Renin-angiotensin system modulation with synthetic angiotensin (1\u20137) and angiotensin II Type 1 receptor-biased ligand in adults with COVID-19. JAMA. 2023;329:1170\u201382.","journal-title":"JAMA"},{"key":"4739_CR80","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2023.10783","volume":"330","author":"RAS dos Santos","year":"2023","unstructured":"dos Santos RAS, Taccone FS, Annoni F. Renin-angiotensin system modulation in adults with COVID-19. JAMA. 2023;330:663\u20134.","journal-title":"JAMA"},{"key":"4739_CR81","doi-asserted-by":"crossref","first-page":"00848","DOI":"10.1183\/23120541.00848-2020","volume":"7","author":"D van Lier","year":"2021","unstructured":"van Lier D, Kox M, Santos K, van der Hoeven H, Pillay J, Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7:00848\u20132020.","journal-title":"ERJ Open Res"},{"key":"4739_CR82","doi-asserted-by":"crossref","first-page":"00342","DOI":"10.1183\/23120541.00342-2022","volume":"9","author":"D van Lier","year":"2023","unstructured":"van Lier D, Deniau B, Santos K, Hartmann O, Dudoignon E, Depret F, et al. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study. ERJ Open Res. 2023;9:00342\u20132022.","journal-title":"ERJ Open Res"},{"key":"4739_CR83","doi-asserted-by":"crossref","unstructured":"Wieruszewski PM, Coleman PJ, Levine AR, Davison D, Smischney NJ, Kethireddy S, et al. Trajectory of PaO 2 \/FiO 2 Ratio in Shock After Angiotensin II. J Intensive Care Med. 2023;088506662311748.","DOI":"10.1177\/08850666231174870"},{"key":"4739_CR84","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jama.2023.4480","volume":"329","author":"Writing Committee for the REMAP-CAP Investigators","year":"2023","unstructured":"Writing Committee for the REMAP-CAP Investigators. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19. JAMA. 2023;329:1183\u201396.","journal-title":"JAMA"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04739-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:48:13Z","timestamp":1700491693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04739-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4739"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04739-5","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}